CSL Behring's Kcentra wins FDA nod as antidote to warfarin

The FDA has approved CSL Behring's prothrombin complex concentrate Kcentra as a reversal agent for the anticoagulant warfarin. Health care providers will not need to match Kcentra with a patient's blood type, so it can be used faster than plasma to reverse the effects of warfarin. It cannot be used to reverse the effects of newer anticoagulants dabigatran and rivaroxaban.

View Full Article in:

Los Angeles Times (tiered subscription model) · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA